Depression is seen in 9-11% of ALS patients and adequate and proper treatment is needed. In
this study, ALS patients will be screened for depression using self-reported multiple choice
questionnaire. Patients who fulfill the criteria for depression based on this screening tool
will be evaluated by psychiatrist before inclusion in the study. The investigators will also
measure quality of life and functional status by simple questionnaires. The patients will be
allocated into two treatment groups to receive either TCA or SSRI for 12 weeks. Patients will
be evaluated every 4 weeks and phone calls will be made in between the visits if needed to
assess about efficacy and any side effects. If any patient reports having suicidal thoughts
on any of these phone calls or clinic visits, he/she will be immediately sent to the ER for
appropriate management. The investigators will repeat the questionnaires in the clinic
visits, and use them in the data analysis to look for any improvement and to compare the two
medication classes used in this study. This data may be used later on to do larger studies
and help to make standard recommendations in treating depression in ALS patients.